Gainers

• ShiftPixy, Inc. (NASDAQ:PIXY) shares rose 69.9% to $0.7391 in pre-market trading. The company announced the effective date for its reverse stock split after the close. Shareholders voted to approve a reverse split on Aug. 21. After the closing bell on Tuesday, ShiftPixy said the one-for-twenty-four reverse split will take effect on Sept. 30.
• MSP Recovery, Inc. (NASDAQ:LIFW) shares rose 41.7% to $0.2155 in pre-market trading after falling around 25% on Tuesday.
• Cardiff Oncology, Inc. (NASDAQ:CRDF) shares gained 35.8% to $2.20 in pre-market trading after the company announced clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity from onvansertib monotherapy.
• Galecto, Inc. (NASDAQ:GLTO) shares rose 30.2% to $0.7470 in pre-market trading after the company announced plans to explore strategic alternatives.
• AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shares surged 20.8% to $0.6999 in pre-market trading.
• Gaucho Group Holdings, Inc. (NASDAQ:VINO) gained 14.8% to $2.40 in pre-market trading after falling over 12% on Tuesday. Gaucho Group recently announced a 1-for-10 reverse stock split.
• Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares jumped 11.4% to $0.64 in pre-market trading. Galmed Pharmaceuticals recently announced the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.
• Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) rose 10.7% to $0.4340 in pre-market trading after falling 8% on Tuesday. The FDA recently said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company's ALS therapy is reasonably likely to predict clinical benefit.
• ThermoGenesis Holdings, Inc. (NASDAQ:THMO) rose 9.9% to $1.44 in pre-market trading after gaining around 12% on Tuesday.
• Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares climbed 8.6% to $0.1640 in pre-market trading after falling 7% on Tuesday. Avalo Therapeutics announced the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance.

Losers

Now Read This: Fear Among US Investors Is Increasing, Here's Why